Urogen Pharma (URGN)
NASDAQ:URGN
Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$22.54
-$0.02(-0.18%)
At close: 4:00 PM EST
$22.54
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$4.71 - $32.37
Previous CloseN/A
Volume157.75K
Average Volume (3M)893.83K
Market Cap
$1.37B
Enterprise Value$1.46B
Total Cash (Recent Filing)$141.60M
Total Debt (Recent Filing)$197.09M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding48,721,703
10 Day Avg. Volume663,441
30 Day Avg. Volume893,828
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue10.37
Enterprise Value/Gross Profit11.54
Enterprise Value/Ebitda-12.51
Forecast
1Y Price Target
$36.63Price Target Upside62.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$263.29M
Bulls Say, Bears Say
Bulls Say
Robust Revenue Growth And Very High Gross MarginsSustained triple‑digit growth into 2026 and persistently ~88–90% gross margins indicate the core product and delivery approach generate high incremental margins. That structural margin profile supports operating leverage as sales scale, enabling durable profitability potential once fixed costs and launch expenses normalize.
ZUSDURI Early Commercial Traction And Prescriber ExpansionRapid prescriber adoption, rising repeat use and shorter PEF‑to‑start cycles reflect meaningful commercialization progress. These durable improvements in access, conversion and prescriber repeatability lower commercial execution risk and support a scalable revenue base if the company continues to convert the broader addressable market.
Late‑stage Pipeline With Consistent Durability Data And NDA PathRobust UGN‑103 durability data and a defined NDA timing materially expand the franchise beyond existing products. A successful approval would diversify revenue, leverage the intravesical platform, and reduce single‑product dependence, improving long‑term growth visibility and strategic optionality.
Bears Say
Weakened Balance Sheet: Negative Shareholder Equity And Rising DebtNegative equity combined with materially higher leverage constrains financial flexibility and increases refinancing and covenant sensitivity. Over the medium term this can limit strategic options, require asset encumbrance (as seen in secured loans), and raise the cost and complexity of future financing.
Persistent Operating Cash Burn And Negative Free Cash FlowSizable and worsening negative operating and free cash flow mean the company will remain reliant on external capital for several quarters. This structural cash burn elevates dilution or leverage risk, limits reinvestment flexibility, and makes execution contingent on continued access to financing until break‑even operations are achieved.
High Launch Spend And Sustained Elevated Operating Expense GuidanceElevated SG&A tied to product launches and a guidance‑level run rate of ~$240–250M keep profitability distant despite revenue growth. Persistent high operating expenses increase the time to leverage gross margins into net profits and raise the hurdle for sustained cash flow improvement absent marked revenue acceleration or cost reduction.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $4.71 and its highest was $32.37 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.37B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 06, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.012.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.3.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,721,703 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 10.155%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.63 (62.49% Upside)
$36.63 (62.49% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 28.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
448.34%
12-Months-Change
Fundamentals
Return on Equity
121.52%
Trailing 12-Months
Asset Growth
2.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong early commercial traction for ZUSDURI with robust revenue growth, improving prescriber metrics, better conversion timelines, and a solid pipeline with near-term regulatory milestones. These positives are tempered by elevated SG&A related to the launch, ongoing net losses, limited current prescriber penetration relative to long-term targets, and continued uncertainty around full-year ZUSDURI revenue. On balance, the company is demonstrating accelerating commercial momentum and advancement of programs while managing costs and liquidity.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$36.63
▲(62.49% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.93% Insiders
5.16% Mutual Funds
52.66% Other Institutional Investors
34.09% Public Companies and
Individual Investors